Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
HaliInatumika, sio kuajiri
Wadhamini
University of Texas Southwestern Medical Center

Maneno muhimu

Kikemikali

PET has an established role in the initial staging of patients with newly diagnosed lung and gastrointestinal tumors.PET avidity is described with both maximum and mean standardized uptake values.Malignant cells have increased activity on PET, defined as the standardized uptake value (SUV), with increased uptake of FDG in tumor due to elevated levels of GLUT receptors, elevated intracellular levels of hexokinase and increased rates of glycolysis. However, there is a subset of patients with lung and gastrointestinal tumors that are not PET avid.These patients may present with clinically and systemically aggressive disease with a declining performance status and/or weight loss.

Maelezo

This study will be a retrospective review of patients in the tumor registry with lung and gastrointestinal tumors, not limited to but including small and non-small cell lung cancers, stomach cancer, small intestinal cancer, colon cancer, rectal cancer, liver and intrahepatic bile duct cancers, gallbladder and extrahepatic bile duct cancers, and pancreatic cancer.

There will be a maximum of 10,000 charts/records that will be reviewed to compile the data. Data to be collected will include patients' name, medical record number, date of birth, race, ethnicity, gender, medical history, medications, vital and performance status, vital signs including weight and body mass index, date of cancer diagnosis, clinical and pathologic stage, pathology, treatment course, prior treatment, location of primary lesion, and smoking history. CT and PET findings to be reviewed include the number of involved lymph nodes, size of primary tumor, average/maximum PET avidity in both the primary tumor and involved lymph nodes.

Tarehe

Imethibitishwa Mwisho: 05/31/2020
Iliyowasilishwa Kwanza: 05/13/2018
Uandikishaji uliokadiriwa Uliwasilishwa: 06/20/2018
Iliyotumwa Kwanza: 06/25/2018
Sasisho la Mwisho Liliwasilishwa: 06/24/2020
Sasisho la Mwisho Lilichapishwa: 06/25/2020
Tarehe halisi ya kuanza kwa masomo: 11/25/2013
Tarehe ya Kukamilisha Msingi iliyokadiriwa: 05/25/2023
Tarehe ya Kukamilisha Utafiti: 02/14/2025

Hali au ugonjwa

Cachexia; Cancer

Uingiliaji / matibabu

Other: Retrospective study

Awamu

-

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza 18 Years Kwa 18 Years
Jinsia Inastahiki KujifunzaAll
Njia ya sampuliNon-Probability Sample
Hupokea Wajitolea wa AfyaNdio
Vigezo

Inclusion Criteria:

1. Patients with histologically proven lung and gastrointestinal cancers, stages I-IV with PET and/or CT within 6 weeks of diagnosis.

2. Patients are greater than 18 years of age.

3. Patients understand a written informed consent document and are willing to sign the consent form.

Exclusion Criteria:

1. Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.

2. Children (under age of 18)

Matokeo

Hatua za Matokeo ya Msingi

1. POTENTIAL BENEFITS [10 years]

The goal of this assessment is to identify patients with lung and gastrointestinal tumors and collect the data on tumor stage location, histology, PET avidity, and weight loss/performance status so that it will be possible to correlate SUV values associated with cachexia by using CTCAE version 4.0 to collect and log AE and SAE related to cachexia. Since, this is a retrospective study no patients is contacted only patient charts are used to study cachexia-inducing tumors which will allow an early intervention to combat cachexia by correlating SUV values associated with cachexia. This retrospective study would help in the early intervention of cachexia induced weight loss and poor performance status.

Jiunge na ukurasa
wetu wa facebook

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

  • Inafanya kazi katika lugha 55
  • Uponyaji wa mitishamba unaungwa mkono na sayansi
  • Kutambua mimea kwa picha
  • Ramani ya GPS inayoshirikiana
  • Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
  • Tafuta mimea ya dawa na athari zao
  • Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa

Google Play badgeApp Store badge